Atopic dermatitis is an important comorbidity in severe asthma.

[1]  R. Olivenstein,et al.  Asthma biomarkers in the age of biologics , 2017, Allergy, Asthma & Clinical Immunology.

[2]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[3]  S. Alhassan,et al.  Asthma , 2016, Critical care nursing quarterly.

[4]  Stephan Weidinger,et al.  Atopic dermatitis , 2016, The Lancet.

[5]  S. Wenzel,et al.  Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. , 2015, The Journal of allergy and clinical immunology.

[6]  J. Silverberg,et al.  Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. , 2013, The Journal of allergy and clinical immunology.

[7]  H. Ortega,et al.  Novel targeted therapies for eosinophilic disorders. , 2012, The Journal of allergy and clinical immunology.

[8]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[9]  D. Leung,et al.  Immunologic, microbial, and epithelial interactions in atopic dermatitis. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[10]  A. Sicras-mainar,et al.  Economic Impact of Atopic Dermatitis in Adults: A Population-Based Study (IDEA Study). , 2018, Actas dermo-sifiliograficas.

[11]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.